Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENDRA Life Sciences (NDRA) Cash & Equivalents (2016 - 2025)

ENDRA Life Sciences has reported Cash & Equivalents over the past 6 years, most recently at $9.5 million for Q4 2021.

  • Quarterly Cash & Equivalents rose 30.91% to $9.5 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $9.5 million through Dec 2021, up 30.91% year-over-year, with the annual reading at $9.5 million for FY2021, 30.91% up from the prior year.
  • Cash & Equivalents was $9.5 million for Q4 2021 at ENDRA Life Sciences, down from $11.8 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $16.8 million in Q1 2021 and troughed at $133679.0 in Q1 2017.
  • The 5-year median for Cash & Equivalents is $4.8 million (2017), against an average of $5.7 million.
  • Year-over-year, Cash & Equivalents surged 9136.41% in 2017 and then crashed 90.87% in 2018.
  • A 5-year view of Cash & Equivalents shows it stood at $5.6 million in 2017, then grew by 15.52% to $6.5 million in 2018, then fell by 4.59% to $6.2 million in 2019, then rose by 17.06% to $7.2 million in 2020, then skyrocketed by 30.91% to $9.5 million in 2021.
  • Per Business Quant, the three most recent readings for NDRA's Cash & Equivalents are $9.5 million (Q4 2021), $11.8 million (Q3 2021), and $14.0 million (Q2 2021).